Immupharma (IMM)

 

IMM Share PerformanceMore

52 week high48.875 02/06/16
52 week low19.100 04/12/15
52 week change -2.500 (-6.33%)
4 week volume2,243,797 31/08/16

Latest NewsMore

ImmuPharma update on Lupuzor study

ImmuPharma, the specialist drug discovery and development company, has issued a further update on the progress of its p...

UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY

RNS Number: 7530J Immupharma PLC 14 September 2016 FOR IMMEDIATE RELEASE 14 SEPTEMBER 2016 ImmuPharma PLC ("ImmuPharma" or the "Company") UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY 11 US Sites Now Open 5 European Countries Now Recruiting ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and developm...

ImmuPharma to open new site in Lupuzor study

ImmuPharma has been asked to open a new site in Mauritius as part of the phase III clinical trial of Lupuzor, the group's l...

UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY

RNS Number: 1275J Immupharma PLC 07 September 2016 RNS: FOR IMMEDIATE RELEASE 7 SEPTEMBER 2016 ImmuPharma PLC ("ImmuPharma" or the "Company") UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY ImmuPharma Invited to Open an Additional Site in Mauritius Up to 30 Lupus patients ready for enrolment ImmuPharma PLC (LS...

Holding(s) in Company

RNS Number: 8466E Immupharma PLC 21 July 2016 RNS: FOR IMMEDIATE RELEASE 21 JULY 2016 ImmuPharma PLC ("ImmuPharma" or the "Company") TR1 NOTIFICATION OF MAJOR INTEREST BY AVIVA ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, announces that it has received a TR-1 by Aviva plc ("A...

Broker Forecast - Northland Capital issues a broker note on ImmuPharma PLC

Northland Capital today initiates coverage of ImmuPharma PLC (LON:IMM) with a buy investment rating and price targ...

Holding(s) in Company

RNS Number: 0441D Immupharma PLC 01 July 2016 RNS: FOR IMMEDIATE RELEASE 1 JULY 2016 ImmuPharma PLC ("ImmuPharma" or the "Company") TR1 NOTIFICATION OF MAJOR INTEREST BY AVIVA ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, announces that it has today received a TR-1 by Aviva p...

Second Price Monitoring Extn

RNS Number: 4019C Immupharma PLC 27 June 2016 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determined percen...

Fundamental DataMore

EPS-4.4
Dividend yield0 %

Latest discussion posts More

  • Lupuzor update

    "ImmuPharma has announced that it has been invited to open an additional site in Mauritius as part of its Phase III clinical trial of Lupuzor?, its lead programme for the ...
    7-Sep-2016
    Sambram
  • Re: SP ACTION

    Tail wagging the dog again!
    11-Aug-2016
    rpg7
  • Re: Lupuzor trial steps up

    Two notes out this morning (both on research tree): Panmure: "Last week, ImmuPharma hosted a symposium featuring Prof Sylviane Muller, the inventor of Lupuzor, detailing ...
    14-Jun-2016
    Simbr

Users' HoldingsMore

Users who hold Immupharma also hold..
LLOYDS GRP.28%
BP22%
ROYAL BANK SCOT13%
GLAXOSMITHKLINE12%
BARCLAYS10%

Codes & Symbols

ISINGB0033711010
SymbolsIMM, LSE:IMM, IMM.L, IMM:LN, LON:IMM, XLON:IMM